Past 10 year's financial track record analysis by Moneyworks4me indicates that Kronox Lab Sciences Ltd is a average quality company.
The key valuation ratios of Kronox Lab Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Kronox Lab Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 50.7% | 55.3% | 51.6% | 51.5% | - |
| Value Creation Index ⓘ | 2.6 | 3.0 | 2.7 | 2.7 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||
| Sales ⓘ | 62.5 | 82.3 | 95.6 | 89.9 | 90 |
| Sales YoY Gr. | - | 31.7% | 16.2% | -6% | - |
| Adj EPS ⓘ | 2.5 | 3.4 | 4.2 | 5.7 | 5.8 |
| YoY Gr. | - | 39.4% | 23.6% | 34.7% | - |
| BVPS (₹) ⓘ | 6.9 | 10.3 | 12.1 | 17.9 | 20.8 |
| Adj Net Profit ⓘ | 9.6 | 13.4 | 15.7 | 21.2 | 21 |
| Cash Flow from Ops. ⓘ | 11.3 | 9 | 19.7 | 17.4 | - |
| Debt/CF from Ops. ⓘ | 0 | 0.1 | 0 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 12.9% | -6% | ||||
| Adj EPS ⓘ | NA | NA | 32.4% | 34.7% | ||||
| BVPSⓘ | NA | NA | 37.5% | 48.2% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 35.8 | 39.9 | 37 | 38.2 | 29.8 |
| Op. Profit Mgn % ⓘ | 23.7 | 24 | 22.7 | 31.5 | 33 |
| Net Profit Mgn % ⓘ | 15.4 | 16.3 | 16.5 | 23.6 | 23.7 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 0 | 151 | 146 | 157 | 92 |
| Cash Conv. Cycle ⓘ | 0 | 69 | 70 | 68 | 77 |
Sales growth is growing at healthy rate in last 3 years 12.89%
Net Profit is growing at healthy rate in last 3 years 32.40%
Return on Equity has declined versus last 3 years average to 29.70%
Sales growth is not so good in last 4 quarters at 4.65%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 5.8 | - |
| TTM Sales (₹ Cr.) | 89.9 | - |
| BVPS (₹.) ⓘ | 20.8 | - |
| Reserves (₹ Cr.) ⓘ | 40 | - |
| P/BV ⓘ | 7.82 | - |
| PE ⓘ | 28.25 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 138.00 / 200.55 |
| All Time Low / High (₹) | 138.00 / 200.55 |
| Market Cap (₹ Cr.) | 603 |
| Equity (₹ Cr.) | 37.1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 56.4 |
| Pledged * | 0.00 | 0.00 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Sales | 62 | 82 | 96 | 90 |
| Operating Expenses ⓘ | 48 | 63 | 74 | 62 |
| Manufacturing Costs | 4 | 4 | 5 | 6 |
| Material Costs | 34 | 47 | 55 | 46 |
| Employee Cost | 1 | 2 | 2 | 3 |
| Other Costs ⓘ | 7 | 9 | 12 | 7 |
| Operating Profit ⓘ | 15 | 20 | 22 | 28 |
| Operating Profit Margin (%) | 23.7% | 23.9% | 22.7% | 31.5% |
| Other Income ⓘ | 1 | 1 | 2 | 2 |
| Interest ⓘ | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 2 | 2 | 1 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 13 | 18 | 22 | 29 |
| Tax ⓘ | 3 | 5 | 6 | 7 |
| Profit After Tax | 10 | 14 | 16 | 21 |
| PAT Margin (%) | 15.6% | 16.6% | 17.2% | 23.8% |
| Adjusted EPS (₹) | 2.5 | 3.5 | 4.4 | 5.8 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 9% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 27 | 40 | 45 | 66 | ||||||
| Share Capital ⓘ | 0 | 0 | 37 | 37 | ||||||
| Reserves ⓘ | 27 | 40 | 8 | 29 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | ||||||
| Debt | 0 | 0 | 0 | 0 | ||||||
| Long Term Debt | 0 | 0 | 0 | 0 | ||||||
| Short Term Debt | 0 | 0 | 0 | 0 | ||||||
| Trade Payables | 7 | 12 | 8 | 6 | ||||||
| Others Liabilities ⓘ | 4 | 4 | 1 | 1 | ||||||
| Total Liabilities ⓘ | 37 | 56 | 54 | 74 | ||||||
Fixed Assets | ||||||||||
| Gross Block | 18 | 22 | 26 | 37 | ||||||
| Accumulated Depreciation | 9 | 10 | 10 | 11 | ||||||
| Net Fixed Assetsⓘ | 9 | 11 | 16 | 26 | ||||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | ||||||
| Investmentsⓘ | 0 | 0 | 0 | 0 | ||||||
| Inventories | 5 | 8 | 9 | 9 | ||||||
| Trade Receivables | 15 | 26 | 19 | 18 | ||||||
| Cash Equivalents | 2 | 3 | 4 | 4 | ||||||
| Others Assetsⓘ | 5 | 9 | 6 | 16 | ||||||
| Total Assets ⓘ | 37 | 56 | 54 | 74 | ||||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 11 | 9 | 20 | 17 |
| PBT ⓘ | 13 | 18 | 22 | 29 |
| Adjustment ⓘ | 2 | 2 | 1 | 1 |
| Changes in Working Capital ⓘ | -1 | -7 | 2 | -4 |
| Tax Paid ⓘ | -4 | -5 | -6 | -7 |
| Cash Flow From Investing Activity ⓘ | -3 | -8 | -7 | -17 |
| Capex | -2 | -4 | -8 | -12 |
| Net Investments | -2 | -4 | 0 | -6 |
| Others ⓘ | 0 | 0 | 1 | 1 |
| Cash Flow From Financing Activityⓘ | -7 | -1 | -13 | 0 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 |
| Others ⓘ | -7 | 0 | -13 | 0 |
| Net Cash Flow ⓘ | 1 | 1 | 0 | 0 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 36.29 | 40.58 | 38.55 | 38.45 | ||||||
| ROCE (%) | 50.71 | 55.32 | 51.63 | 51.52 | ||||||
| Asset Turnover Ratio | 1.67 | 1.75 | 1.74 | 1.41 | ||||||
| PAT to CFO Conversion(x) | 1.1 | 0.64 | 1.25 | 0.81 | Working Capital Days | |||||
| Receivable Days | 90 | 92 | 85 | 74 | ||||||
| Inventory Days | 32 | 29 | 32 | 37 | ||||||
| Payable Days | 70 | 70 | 64 | 56 | ||||||
The company was incorporated on November 18, 2008 as 'Kronox Lab Sciences Private Limited', a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 18, 2008 issued by the Assistant Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Subsequently, the company was converted into a public limited company pursuant to a resolution passed by its shareholders at an extra-ordinary general meeting held on May 25, 2019 and a fresh certificate of incorporation dated June 11, 2019 was issued by the Registrar of Companies, Ahmedabad consequent upon conversion, recording the change in the name of the company to 'Kronox Lab Sciences Limited'.
The company manufactures High Purity Speciality Fine Chemicals for diversified end user industries. Its High Purity Speciality Fine Chemicals are used mainly as (i) reacting agents and raw material in the manufacturing of Active Pharmaceutical Ingredients (APIs); (ii) excipients in pharmaceutical formulations; (iii) reagents for scientific research and laboratory testing; (iv) ingredients in nutraceuticals formulations; (v) process intermediates and fermenting agents in biotech applications; (vi) ingredients in agrochemical formulations; (vii) ingredients in personal care products; (viii) refining agents in metal refineries; and (ix) ingredients in animal health products, amongst others. Its products are manufactured in accordance with industry standards like IP, BP, EP, JP, USP, FCC, LR, AR, GR and ACS in addition to custom manufacturing specifications, which differ from the industry standards, required by its customers in select cases. It manufactures High Purity Speciality Fine Chemicals of various grades in particle sizes ranging from 10 mesh to 100 mesh. Its focus on product development, diversity in product offerings, meeting quality standards and customer specifications and continuous process improvement has led to repeat orders from its customers over the years.
In addition to the manufacturing of products in accordance with various domestic and international standards, it also undertakes custom manufacturing to achieve high levels of purity, as specified by the client, having different purity levels than the prescribed industry standards. Custom manufacturing requires deep domain knowledge, expertise and understanding of the characteristics of each chemical and its compounds, including decreasing the level of existing impurities and the processes to be deployed to reach the desired level of purity. It has set up an in-house research, development and testing laboratory (RDT Laboratory) to develop new products and test its products against the specified industry standards or customer specifications. Its dedicated RDT Laboratory is located in Unit I with the objective to implement a performance-oriented approach with the help of advanced equipment and systems. Its RDT Laboratory is equipped with the necessary facilities to carry out tests required to develop the products.
Business area of the company
The company is a bulk manufacturer of high purity fine chemicals, in compliance with Reagent, Pharmacopoeia and various Food Grade standards, for the pharmaceutical, nutraceutical, veterinary, food, chemical analysis and other specialty markets.
Major events:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
